Catalog Products » DSG3, His, Human
Manual
Manual
COAs

DSG3, His, Human

To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
$340.00
Z05228-100

Ask us a question
Product Introduction
Species Human
Protein Construction
DSG3 (Glu50-Arg615)
Accession # P32926		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 64 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

DSG3, His, Human

Immobilized DSG3, His, Human, His Tag at 0.5 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-DSG3 Antibody, hFc Tag with the EC50 of 2.4ng/ml determined by ELISA. »

DSG3, His, Human

The purity of DSG3, His, Human is greater than 90% as determined by SEC-HPLC. »

DSG3, His, Human

DSG3, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
Synonyms Desmoglein-3; PVA; CDHF6; SG3; DSG3; DSG-3
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.